Incyte/Morphosys take on CAR-Ts with $198,000 per year antibodyIncyte and Morphosys’ Monjuvi antibody therapy has been approved for certain patients with lymphoma, as the companies hope Share XIncyte/Morphosys take on CAR-Ts with $198,000 per year antibodyhttps://pharmaphorum.com/news/incyte-morphosys-take-on-car-ts-as-lymphoma-antibody-monjuvi-approved-in-us/
ADC Therapeutics sets terms for $125m IPOSwiss cancer drugs firm ADC Therapeutics has set the terms for a $125 million IPO to further develop Share XADC Therapeutics sets terms for $125m IPOhttps://pharmaphorum.com/news/adc-therapeutics-sets-terms-for-125m-ipo/
Gilead to buy immuno-oncology firm Forty Seven for $4.9bnGilead is to buy immuno-oncology firm Forty Seven for $4.9 billion, adding an antibody targeting several blood cancers Share XGilead to buy immuno-oncology firm Forty Seven for $4.9bnhttps://pharmaphorum.com/news/gilead-to-buy-immuno-oncology-firm-forty-seven-for-4-9bn/
NICE rejects Roche’s Polivy combination in advanced lymphomaEngland’s NHS should not fund Roche’s Polivy (polatuzumab vedotin) in combination with rituximab and bendamustine for adults with Share XNICE rejects Roche’s Polivy combination in advanced lymphomahttps://pharmaphorum.com/news/nice-rejects-roches-polivy/
